Opinion|Videos|July 31, 2024
Treatment Paradigms for Clinical Progression of CLL/SLL Beyond Initial Therapies
Author(s)Mazyar Shadman, MD, MPH
An expert on CLL/SLL provides clinical insights on approaching the treatment of patients who progress beyond initial therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How do you approach treatment for patients that progress beyond initial therapy in CLL/SLL?
- What factors influence the choice of retreatment options after prior BTK inhibitor therapy?
- What factors influence the choice of retreatment options after prior BTK inhibitor therapy?
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5